Remembering Paul Tsongas and Understanding Lymphoma

What the record shows

Paul Tsongas left the U.S. Senate in 1984 after being diagnosed with lymphoma. He returned to national politics and ran for the Democratic presidential nomination in 1992.

UPI reported the rest of the timeline after his death. Tsongas had two bone marrow transplants. He had two recurrences after 1984, one in 1987 and a second in 1992, shortly after his unsuccessful presidential bid. Earlier in January 1997 he had surgery to clear a blockage in his liver. His doctors said that blockage was related to the second bone marrow transplant, which he had received the previous year.

He died on the night of Saturday, January 18, 1997, of pneumonia, at 55. UPI reported that at the time of his death his doctors said he was cancer-free. His family asked that memorial donations go to the Dana-Farber Cancer Institute.

That is the public record, and this article does not add to it. What follows is the disease, and one part of it that news coverage almost never reaches.

What non-Hodgkin lymphoma is

The lymph system is part of the immune system. The National Cancer Institute lists its parts: lymph, the clear fluid that carries white blood cells; lymph vessels; lymph nodes, the bean-shaped filters in the neck, underarm, chest, abdomen, pelvis, and groin; the spleen; the thymus; the tonsils; and bone marrow.

Non-Hodgkin lymphoma, or NHL, is cancer that forms in that system. It begins in lymphocytes, the white blood cells that run immune defense. B cells make antibodies. T cells help them. Natural killer cells attack infected and abnormal cells.

NCI reports that B-cell lymphomas make up about 85% of NHL cases. For all types of NHL together, the American Cancer Society's projection for 2026 is 79,320 new cases in the United States and 19,970 deaths.

The split that decides everything: indolent or aggressive

NCI divides NHL into two prognostic groups, and the labels are counterintuitive.

Indolent lymphoma grows slowly. NCI describes it as having a relatively good prognosis, with median survival as long as 20 years, but says it is usually not curable in advanced stages. Early-stage indolent NHL, meaning stage I and stage II, can be effectively treated with radiation therapy alone. Most indolent lymphomas are follicular in appearance under the microscope.

Aggressive lymphoma grows fast, and NCI says it has a worse prognosis in the short term. But more than 70% of patients with aggressive NHL can be cured. Most relapses happen in the first two years after treatment.

So the slow one is often controlled for decades without a cure. The fast one is frequently cured outright. That inversion catches people off guard. It also explains why two people with "lymphoma" get completely different plans.

When to get checked

NCI says to check with a doctor about any of these:

• Swelling in the lymph nodes of the neck, underarm, groin, or stomach.
• Fever for no known reason.
• Drenching night sweats.
• Feeling very tired.
• Weight loss for no known reason.
• Skin rash or itchy skin.
• Pain in the chest, abdomen, or bones for no known reason.

NCI gives one grouping a name. When fever, drenching night sweats, and unexplained weight loss occur together, they are called B symptoms. That trio carries weight in staging and planning. Report it as a set, not one item at a time.

Practical thresholds:

• A lymph node that is painless, firm, larger than about 1 cm, and still there after two to three weeks, without an infection to explain it.
• Night sweats heavy enough to require changing nightclothes or bedding, continuing more than two weeks.
• Weight loss you did not intend, roughly 10% of body weight or more over six months.
• Fever with no source that keeps returning.

Swollen nodes are common and almost always from infection. Duration, and the lack of an explanation, are what shift the picture.

How it is staged

NHL uses the Ann Arbor system, which counts regions rather than tumor size. SEER describes the four stages plainly. Stage I is confined to a single region. Stage II involves multiple regions. Stage III has spread to both sides of the diaphragm. Stage IV is diffuse or disseminated involvement.

Diagnosis rests on removing a node or tissue sample and examining it. A blood count and imaging fill in the rest.

Transplant, and what it costs later

NCI notes that people with aggressive forms of NHL may reach lasting complete remission with combination chemotherapy. Some get there with aggressive consolidation supported by bone marrow or stem cells.

That is what a bone marrow transplant is for. Very high doses of chemotherapy, sometimes with total-body radiation, wipe out the marrow. Stored blood stem cells are then returned to rebuild it. In an autologous transplant, the cells are the patient's own.

NCI's guidance devotes a section to what happens afterward, and this is the part almost no article covers. Late effects it lists include:

• Impaired fertility after treatment with alkylating agents.
• A raised risk of second primary cancers, for as long as three decades after diagnosis. NCI names lung, brain, kidney, and bladder cancers, melanoma, Hodgkin lymphoma, and acute nonlymphocytic leukemia.
• Left ventricular dysfunction, a weakening of the heart's main pumping chamber, in long-term survivors of high-grade NHL given more than 200 mg/m² of doxorubicin.
• Myelodysplastic syndrome and acute myelogenous leukemia after myeloablative therapy with marrow or stem cell support.
• Late venous thromboembolism, meaning blood clots, after transplant.
• Reduced bone density.

NCI cites one series of 605 patients who had an autologous bone marrow transplant with cyclophosphamide and total-body radiation, followed for a median of ten years. The incidence of a second malignancy was 21%.

This is why long-term follow-up after lymphoma is not a formality. Surviving it starts a second, longer job.

What the numbers describe

These are population figures and do not describe any individual.

The 79,320 new non-Hodgkin lymphomas expected in the United States in 2026, about 3.8% of all new cancer diagnoses, and the 19,970 deaths are American Cancer Society projections shown on SEER's page. Five-year relative survival across all stages is 74.3% for people diagnosed from 2016 to 2022. NHL is most often diagnosed between ages 65 and 74.

By Ann Arbor stage, SEER records five-year relative survival of 87.6% for stage I, 79.7% for stage II, 74.0% for stage III, and 63.6% for stage IV. Note how narrow that range is next to solid tumors. About 37% of cases are stage IV at diagnosis, and stage IV lymphoma still carries five-year relative survival above 60%.

That is the practical difference between lymphoma and most cancers. Widespread disease is not the catastrophe here that it is elsewhere. It is why the words indolent and aggressive matter more than the stage number.

Sources

• NCI: Adult Non-Hodgkin Lymphoma Treatment (PDQ) — Health Professional Version
• NCI: Adult Non-Hodgkin Lymphoma Treatment (PDQ) — Patient Version
• SEER Cancer Stat Facts: Non-Hodgkin Lymphoma
• American Cancer Society: Cancer Facts & Statistics
• UPI Archives: Tsongas's funeral services set (January 20, 1997)